Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Nils A. ‘t Hart"'
Autor:
Judith E. Van Zanden, Nils A. ’T Hart, Petra J. Ottens, Bo Liu, Rolando A. Rebolledo, Michiel E. Erasmus, Henri G. D. Leuvenink
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Background: The process of brain death (BD) leads to a pro-inflammatory state of the donor lung, which deteriorates its quality. In an attempt to preserve lung quality, methylprednisolone is widely recommended in donor lung management. However, clini
Externí odkaz:
https://doaj.org/article/1afef89b4ad54c299630b9dd7e5f6588
Autor:
Daan van den Broek, T. Jeroen N. Hiltermann, Bonne Biesma, Winand N. M. Dinjens, Nils A. 't Hart, John W. J. Hinrichs, Mathie P. G. Leers, Kim Monkhorst, Matthijs van Oosterhout, Volkher Scharnhorst, Ed Schuuring, Ernst-Jan M. Speel, Michel M. van den Heuvel, Ron H. N. van Schaik, Jan von der Thüsen, Stefan M. Willems, Leonie de Visser, Marjolijn J. L. Ligtenberg
Publikováno v:
Frontiers in Oncology, Vol 9 (2020)
The diagnostic landscape of non-small cell lung cancer (NSCLC) is changing rapidly with the availability of novel treatments. Despite high-level healthcare in the Netherlands, not all patients with NSCLC are tested with the currently relevant predict
Externí odkaz:
https://doaj.org/article/690a5016a3c44acc879bb9a893ae5eb8
Autor:
Marjolein Leemkuil, MD, Grietje Lier, MD, Marten A. Engelse, PhD, Rutger J. Ploeg, PhD, Eelco J. P. de Koning, PhD, Nils A. ‘t Hart, PhD, Christina Krikke, MD, Henri G. D. Leuvenink, PhD
Publikováno v:
Transplantation Direct, Vol 4, Iss 10, p e388 (2018)
Background. Transplantation of beta cells by pancreas or islet transplantation is the treatment of choice for a selected group of patients suffering from type 1 diabetes mellitus. Pancreata are frequently not accepted for transplantation, because of
Externí odkaz:
https://doaj.org/article/e8cb835bdc2b41cb883976ee92e06ccd
Autor:
Arenda D. Meedendorp, Arja ter Elst, Nils A. ’t Hart, Harry J. M. Groen, Ed Schuuring, Anthonie J. van der Wekken
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
A 62-year-old man was referred to our university hospital for treatment of advanced adenocarcinoma of the lung after disease progression on two lines of EGFR TKI and one line of chemotherapy. Fluorescent in situ hybridization analysis upon progressio
Externí odkaz:
https://doaj.org/article/b480ae675d6142f99b0db7ea051f9a3c
Autor:
Eline G.M. Steenhuis, Maaike M. Brus, Nils A. ‘t Hart, Liudmila L. Kodach, Jacqueline Nijboer-Oosterveld, Benjamin Tomlow
Publikováno v:
Chest. 161:e233-e240
Publikováno v:
Modern Pathology. 35:326-332
Companion diagnostic immunohistochemistry (IHC) tests are developed and performed without incorporating the tools and principles of laboratory metrology. Basic analytic assay parameters such as lower limit of detection (LOD) and dynamic range are unk
Autor:
Bregje M Koomen, Nils A. 't Hart, Wim Timens, Stefan M. Willems, Judith M. Vonk, Jose van der Starre-Gaal, Kim Monkhorst, Jacqueline J C van der Meij, Jan H. von der Thüsen
Publikováno v:
Cancer Cytopathology
Cancer cytopathology, 129(4), 304-317. Wiley
Cancer cytopathology, 129(4), 304-317. Wiley-Blackwell
Cancer cytopathology, 129(4), 304-317. Wiley
Cancer cytopathology, 129(4), 304-317. Wiley-Blackwell
Background Immunohistochemical staining of programmed death‐ligand 1 (PD‐L1) is used to determine which patients with non–small cell lung cancer (NSCLC) may benefit most from immunotherapy. Therapeutic management of many patients with NSCLC is
Autor:
Erik Thunnissen, Cleo Keppens, Karen Zwaenepoel, Elisabeth Dequeker, Ales Ryska, Jan H. von der Thüsen, Ed Schuuring, Nils A. 't Hart, Patrick Pauwels, Keith Miller
Publikováno v:
Journal of Molecular Diagnostics, 22(12), 1438-1452. Elsevier Inc.
Journal of molecular diagnostics, 22(12), 1438-1452. ELSEVIER SCIENCE INC
The journal of molecular diagnostics
Keppens, C, von der Thüsen, J, Pauwels, P, Ryska, A, ’t Hart, N, Schuuring, E, Miller, K, Thunnissen, E, Zwaenepoel, K & Dequeker, E M C 2020, ' Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non–Small-Cell Lung Cancer ', The Journal of molecular diagnostics, vol. 22, no. 12, pp. 1438-1452 . https://doi.org/10.1016/j.jmoldx.2020.09.006
The Journal of molecular diagnostics, 22(12), 1438-1452. Association of Molecular Pathology
Journal of molecular diagnostics, 22(12), 1438-1452. ELSEVIER SCIENCE INC
The journal of molecular diagnostics
Keppens, C, von der Thüsen, J, Pauwels, P, Ryska, A, ’t Hart, N, Schuuring, E, Miller, K, Thunnissen, E, Zwaenepoel, K & Dequeker, E M C 2020, ' Staining Performance of ALK and ROS1 Immunohistochemistry and Influence on Interpretation in Non–Small-Cell Lung Cancer ', The Journal of molecular diagnostics, vol. 22, no. 12, pp. 1438-1452 . https://doi.org/10.1016/j.jmoldx.2020.09.006
The Journal of molecular diagnostics, 22(12), 1438-1452. Association of Molecular Pathology
Selection of non-small-cell lung cancer patients for treatment relies on the detection of expression of anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1 (ROS1) protein by immunohistochemistry (IHC). We evaluated staining performance for diff
Autor:
Rogier Butter, Liesbeth M. Hondelink, Lisette van Elswijk, Johannes L.G. Blaauwgeers, Elisabeth Bloemena, Rieneke Britstra, Nicole Bulkmans, Anna Lena van Gulik, Kim Monkhorst, Mathilda J. de Rooij, Ivana Slavujevic-Letic, Vincent T.H.B.M. Smit, Ernst-Jan M. Speel, Erik Thunnissen, Jan H. von der Thüsen, Wim Timens, Marc J. van de Vijver, David C.Y. Yick, Aeilko H. Zwinderman, Danielle Cohen, Nils A. 't Hart, Teodora Radonic
Publikováno v:
Butter, R, Hondelink, L M, van Elswijk, L, Blaauwgeers, J L G, Bloemena, E, Britstra, R, Bulkmans, N, van Gulik, A L, Monkhorst, K, de Rooij, M J, Slavujevic-Letic, I, Smit, V T H B M, Speel, E-J M, Thunnissen, E, von der Thusen, J H, Timens, W, van de Vijver, M J, Yick, D C Y, Zwinderman, A H, Cohen, D, 't Hart, N A & Radonic, T 2022, ' The impact of a pathologist's personality on the interobserver variability and diagnostic accuracy of predictive PD-L1 immunohistochemistry in lung cancer ', Lung Cancer, vol. 166, pp. 143-149 . https://doi.org/10.1016/j.lungcan.2022.03.002
Lung Cancer, 166, 143-149. ELSEVIER IRELAND LTD
Lung Cancer, 166, 143-149. Elsevier Ireland Ltd
Lung cancer (Amsterdam, Netherlands), 166, 143-149. Elsevier Ireland Ltd
Lung Cancer, 166, 143-149. ELSEVIER IRELAND LTD
Lung Cancer, 166, 143-149. Elsevier Ireland Ltd
Lung cancer (Amsterdam, Netherlands), 166, 143-149. Elsevier Ireland Ltd
OBJECTIVES: Programmed death-ligand 1 (PD-L1) is the only approved predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). However, predictive PD-L1 immunohistochemistry is subject to interobserver variability. We hypothesized t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e91c4dfdf95aaf2d5c8858a92d701a4
https://research.vumc.nl/en/publications/b0a56853-9990-4cd8-bc42-214dd162e9ce
https://research.vumc.nl/en/publications/b0a56853-9990-4cd8-bc42-214dd162e9ce
Publikováno v:
Modern Pathology. 36:100057